{
    "clinical_study": {
        "@rank": "18262", 
        "arm_group": [
            {
                "arm_group_label": "Ranolazine", 
                "arm_group_type": "Active Comparator", 
                "description": "Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo by mouth twice per day"
            }, 
            {
                "arm_group_label": "Observational", 
                "arm_group_type": "No Intervention", 
                "description": "Patients with pulmonary hypertension who have near normal RV function (RVEF >40%) will undergo same procedures in the observational arm but will not receive an intervention."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is looking to see if giving ranolazine to subjects on stable pulmonary\n      hypertension specific therapies but with right ventricular dysfunction (RVEF <=40%) would\n      improve their outcome. This study is accompanied by a baseline comparison of the metabolic\n      profiling/microRNA/iPS cells of subjects with and without right ventricular dysfunction."
        }, 
        "brief_title": "Targeting the Right Ventricle in Pulmonary Hypertension", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Ventricular Dysfunction, Right", 
                "Ventricular Dysfunction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic pulmonary hypertension based on one of the following criteria: Idiopathic\n             pulmonary arterial hypertension, Familial pulmonary arterial hypertension, pulmonary\n             hypertension associated with connective tissue disease, chronic thromboembolic\n             pulmonary hypertension-nonsurgical/distal vessel disease, simple congenital such as\n             repaired  atrial or ventricular septal defect or unrepaired small  atrial or\n             ventricular septal defect with persistent and out of proportion pulmonary arterial\n             hypertension\n\n          -  WHO functional class II, III, or IV\n\n          -  Mean pulmonary artery pressure >25 mmHg at rest\n\n          -  Pulmonary capillary wedge pressure or left ventricular end diastolic pressure < 15\n             mmHg\n\n          -  Baseline 6-minute walk test distance > 50 meters\n\n          -  Stable on baseline existing PH specific therapy for 12 weeks with no dosage change\n             within 28 days prior to screening.\n\n        Exclusion Criteria:\n\n          -  Previous treatment with or prior sensitivity to ranolazine\n\n          -  Any family history of corrected QT interval prolongation, congenital long QT\n             syndrome, or receiving drugs that prolong the corrected QT interval\n\n          -  Parenchymal lung disease showing total lung capacity < 50% of predicted OR forced\n             expiratory volume at one second/forced vital capacity < 50%\n\n          -  Portal hypertension associated with liver disease\n\n          -  Untreated severe obstructive sleep apnea\n\n          -  Left sided heart disease including any of the following: moderate or greater aortic\n             or mitral valve disease, Any left ventricle cardiomyopathy, Left ventricular systolic\n             dysfunction defined as an ejection fraction < 50%, Symptomatic coronary artery\n             disease\n\n          -  Uncontrolled hypertension\n\n          -  Uncontrolled diabetes\n\n          -  Moderate to severe chronic renal disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839110", 
            "org_study_id": "817785"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ranolazine", 
                "description": "Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.", 
                "intervention_name": "Ranolazine", 
                "intervention_type": "Drug", 
                "other_name": "Ranexa"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo by mouth twice per day for a total of 26 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pulmonary hypertension", 
            "right ventricular function", 
            "ranolazine"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mpark@medicine.umaryland.edu", 
                    "last_name": "Myung Park, MD"
                }, 
                "contact_backup": {
                    "email": "lpoliako@medicine.umaryland.edu", 
                    "last_name": "Lioubov Poliakova"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland"
                }, 
                "investigator": {
                    "last_name": "Myung Park, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "abwaxman@partners.org", 
                    "last_name": "Aaron Waxman, MD, PhD"
                }, 
                "contact_backup": {
                    "email": "llawler@partners.org", 
                    "last_name": "Laurie Lawler, RN"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Aaron Waxman, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yuchi.han@uphs.upenn.edu", 
                    "last_name": "Yuchi Han, MD"
                }, 
                "contact_backup": {
                    "email": "baer2@mail.med.upenn.edu", 
                    "last_name": "Amanda Baer, MB, MBA"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Yuchi Han, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction", 
        "overall_contact": {
            "email": "yuchi.han@uphs.upenn.edu", 
            "last_name": "Yuchi Han, MD", 
            "phone": "215-662-2855"
        }, 
        "overall_contact_backup": {
            "email": "baer2@mail.med.upenn.edu", 
            "last_name": "Amanda Baer, MB, MBA", 
            "phone": "215-746-3423"
        }, 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Yuchi Han, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number and percentage of subjects with high risk profile at Week 26. Patients with high risk profile are defined as patients with clinical worsening events or lack of clinical improvement at the end of the study.", 
            "measure": "Number and percentage of subjects with high risk profile at end of the study", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839110"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "Yuchi Han", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measure differences in glucose and lipid metabolism in subjects with and without RV dysfunction at baseline.", 
                "measure": "Glucose and lipid metabolites", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Measure fold changes in glucose and lipid metabolism in subjects with persistent right ventricle dysfunction after treatment with and without ranolazine.", 
                "measure": "Changes from baseline in glucose and lipid metabolism", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Cardiovascular Medical Research and Education Fund", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Brigham and Women's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Maryland", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Yale University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}